Bluejay Diagnostics, Inc.
BJDX- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001704287
No open-market purchases or sales by Bluejay Diagnostics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $259.3K in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 13, 2026, 1:21 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2026 | – | – | Mar 20, 2023 | Mar 10, 2022 |
| Revenue | – | – | – | $249.0K | – |
| Cost of revenue | – | – | – | $200.1K | – |
| Gross profit | – | – | – | $48.9K | – |
| Operating expenses | $6.95M | $7.17M | $10.3M | $9.37M | $3.23M |
| Research and development | $3.05M | $3.47M | $5.71M | $4.15M | $1.15M |
| Selling, general and administrative | $3.91M | $3.69M | $283.4K | $4.76M | $1.79M |
| Operating income | -$6.95M | -$7.17M | -$10.3M | -$9.32M | -$3.23M |
| Interest expense | – | – | – | – | $6.36K |
| Net income | -$6.85M | -$7.72M | -$9.95M | -$9.30M | -$3.49M |
| EPS, basic | $-15.25 | $-114.19 | $-9.08 | $-0.46 | – |
| EPS, diluted | $-15.25 | $-114.19 | $-9.08 | $-0.46 | – |
| Weighted shares, basic | 449.0K | 183.4K | 1.10M | 20.2M | – |
| Weighted shares, diluted | 449.0K | 183.4K | 1.10M | 20.2M | – |
| Margins and growth | |||||
| Gross margin | – | – | – | 19.6% | – |
| Operating margin | – | – | – | -3741.5% | – |
| Net margin | – | – | – | -3733.1% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2026 | – | – | Mar 20, 2023 | Mar 10, 2022 |
| Cash and equivalents | $5.16M | $4.30M | $2.21M | $10.1M | $19.0M |
| Total current assets | $5.46M | $4.90M | $3.22M | $11.8M | $20.7M |
| Property, plant and equipment | $1.53M | $1.51M | $1.29M | $1.23M | $337.4K |
| Total assets | $7.12M | $6.66M | $4.87M | $13.5M | $21.0M |
| Accounts payable | $214.3K | $145.1K | $491.5K | $635.8K | $295.8K |
| Total current liabilities | $1.12M | $810.4K | $1.77M | $1.64M | – |
| Total liabilities | $1.14M | $927.9K | $1.97M | $1.98M | $637.2K |
| Shareholders' equity | $5.98M | $5.73M | $2.89M | $11.5M | $20.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2026 | – | – | Mar 20, 2023 | Mar 10, 2022 |
| Operating cash flow | -$6.05M | -$7.82M | -$8.31M | -$7.74M | -$4.37M |
| Capital expenditures | $173.7K | $306.8K | $704.2K | $1.20M | $23.9K |
| Free cash flow | -$6.23M | -$8.13M | -$9.02M | -$8.94M | -$4.39M |
| Depreciation and amortization | – | – | – | $156.6K | $145.7K |
| Stock-based compensation | $6 | $20.1K | $189.2K | $433.0K | $68.5K |
| Investing cash flow | -$173.7K | -$306.8K | -$704.2K | -$1.20M | -$23.9K |
| Financing cash flow | $7.09M | $10.2M | $1.11M | $8.07K | $22.5M |
| Net change in cash | – | – | – | -$8.93M | $18.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | – | – | 173.9% | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2026 | 1.12M | −38.4% | SEC |
| Aug 7, 2026 | 4.47M | +199.0% | SEC |
| May 4, 2026 | 1.03M | −30.7% | SEC |
| Mar 2, 2026 | 972.2K | +75.5% | SEC |
| Nov 6, 2025 | 1.81M | −93.3% | SEC |
| Aug 1, 2025 | 1.49M | −76.1% | SEC |
| May 12, 2025 | 1.49M | −48.6% | SEC |
| Apr 28, 2025 | 1.49M | −48.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.